Drug Trial Radar · NCT07544654
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
390
Planned (sponsor's estimate)
Start
Jul 10, 2026
Primary completion
Dec 13, 2029
Study completion Dec 13, 2029
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Apr 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with advanced extrapulmonary neuroendocrine cancer. The purpose of this study is to find out if a study medicine called obrixtamig plus standard chemotherapy (carboplatin and etoposide) improves survival when compared to standard chemotherapy (carboplatin and etoposide) alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker delta-like ligand 3 (DLL3). Participants are put into 2 groups randomly, which means by chance. One group (treatment arm) receives obrixtamig and standard chemotherapy followed by obrixtamig alone for up to 3 years. The other group (control arm) receives standard chemotherapy without obrixtamig for about 4 months. All treatments are given as infusions into a vein. During the study, participants in both groups visit the study site regularly. Participants in the treatment arm stay overnight at the study site following the first 2 obrixtamig treatments. The doctors regularly check participants' health and take note of any unwanted effects. At some of the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works.
Conditions
- Extrapulmonary Neuroendocrine Cancer (epNEC)
Interventions
ObrixtamigDrug
Obrixtamig
CarboplatinDrug
Carboplatin
EtoposideDrug
Etoposide
Ventana DLL3 RxDx assayDevice
Ventana DLL3 RxDx assay
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Up to 38 months
Locations
170 sites in 29 countries. Site status is shown where the registry gives one.
Mayo Clinic
Scottsdale, Arizona · Not yet recruiting
City of Hope-Duarte-56419
Duarte, California · Recruiting
University of California San Francisco
San Francisco, California · Not yet recruiting
University of California Los Angeles
Santa Monica, California · Not yet recruiting
Mayo Clinic - Florida
Jacksonville, Florida · Not yet recruiting
Emory University
Atlanta, Georgia · Recruiting
The University of Chicago Medical Center
Chicago, Illinois · Not yet recruiting
The Skip Viragh Outpatient Cancer Research Building
Baltimore, Maryland · Not yet recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Not yet recruiting
Mayo Clinic, Rochester
Rochester, Minnesota · Not yet recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Memorial Sloan-Kettering Cancer Center
New York, New York · Not yet recruiting
The Ohio State University Wexner Medical Center
Columbus, Ohio · Not yet recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Not yet recruiting
University of Tennessee
Knoxville, Tennessee · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee · Not yet recruiting
Baylor University Medical Center
Dallas, Texas · Not yet recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Not yet recruiting
Huntsman Cancer Institute
Salt Lake City, Utah · Not yet recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington · Not yet recruiting
Centro Medico Reumatologico - OMI
CABA, Argentina · Recruiting
Hospital Britanico de Buenos Aires
CABA, Argentina · Recruiting
Instituto Medico Especializado Alexander Fleming
Ciudad Autónoma de Bs As, Argentina · Not yet recruiting
Clinica Privada Independencia
Munro, Argentina · Recruiting
Sanatorio Parque S.A.
Rosario, Argentina · Recruiting
Royal North Shore Hospital
St Leonards, New South Wales, Australia · Recruiting
Flinders Medical Centre
Bedford Park, South Australia, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Fiona Stanley Hospital
Murdoch, Western Australia, Australia · Recruiting
Medical University of Graz
Graz, Austria · Not yet recruiting
Medical University of Vienna
Vienna, Austria · Not yet recruiting
Cliniques Universitaires Saint-Luc
Brussels, Belgium · Recruiting
Universitair Ziekenhuis Antwerpen
Edegem, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Centre Hospitalier Universitaire de Liège
Liège, Belgium · Recruiting
Hospital de Amor
Barretos, Brazil · Recruiting
Instituto D'Or de Pesquisa E Ensino - Pe
Recife, Brazil · Recruiting
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
São José do Rio Preto, Brazil · Recruiting
ICESP - Instituto do Cancer do Estado de Sao Paulo
São Paulo, Brazil · Recruiting
Showing 40 of 170 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.